Department Of Infectious Disease
Investigator
Magdalena Sobieszczyk, MD
Phone
212-305-7185
Email
mes52@cumc.columbia.edu
Dr. Magdalena Sobieszczyk is the PI of the NIH-funded Columbia HVTN and ACTG Clinical Research Site. Her research focuses on developing, testing, and implementation of biomedical strategies to prevent HIV infection, specifically preventive HIV vaccines and pre-exposure prophylaxis (PrEP). Particular interests include assessing combination biomedical prevention strategies such as vaccines together with oral and topical PrEP; and evaluating host factors influencing immunologic and virologic course of HIV disease and response to vaccination in study participants. She has been involved in the development and implementation of several international and national HIV prevention protocols and is the co-chair of phase 2b HIV vaccine protocol to determine the safety and efficacy of the DNA prime-Ad5 boost vaccine regimen in individuals at risk of HIV infection (HVTN 505).

Her research with HIV infected individuals includes investigating HIV testing and linkage to care in the predominantly Latino communities of northern Manhattan. This also includes describing the prevalence of metabolic and renal abnormalities in this population and in South African cohorts.

Dr. Sobieszczyk is also a co-investigator of the Centre for the AIDS Program of Research in South Africa (CAPRISA) project entitled “Viral Setpoint and Clinical Progression in HIV-1 Subtype C Infection: The Role of Immunological and Viral Factors During Acute and Early Infection” (Salim Abdool Karim, PI).


Clinical Studies Managed By This Investigator:
Condition Study Title
HIV [ CLOSED ] A phase 1/2a HIV vaccine study designed to test the safety and immune responses of different vaccine combinations among HIV adults.
HIV HIV Prevention Study
Healthy Volunteers HIV Prevention Study
Healthy Volunteers [ CLOSED ] Antibodies for HIV Prevention
HIV [ CLOSED ] Antibodies against HIV
Healthy Volunteers [ CLOSED ] HIV prevention study: HVTN 120
Healthy Volunteers [ CLOSED ] Bispecific Antibody Study: 18-60-year-old, Healthy & HIV-Negative Volunteers
HIV [ CLOSED ] Bispecific Antibody Study for 18-60-year-old People Who Live With HIV/AIDS
Healthy Volunteers [ CLOSED ] HIV Vaccine Study Among 18-60 year-old Sexually Active Men or Transgender Individuals
Healthy Volunteers [ CLOSED ] A Study Among 18-50 Year Old People Who Do NOT Have HIV Comparing an Antibody in Combination with 3 Different Antibodies (CUIMC)
COVID-19 (Coronavirus) [ CLOSED ] Study of Sarilumab for Patients Hospitalized with COVID-19
COVID-19 (Coronavirus) ARMOR Study: A Study to Follow COVID-19 Antibodies Over Time
COVID-19 (Coronavirus) [ CLOSED ] A study to describe immune responses in study participants with a history of infection with SARS-CoV-2, the virus that causes COVID-19
COVID-19 (Coronavirus) Screening for COVID-19 vaccine, prevention and treatment research studies
Healthy Volunteers [ CLOSED ] HVTN 137: HIV Vaccine Trial for Healthy, HIV Negative Adults, Ages 18-50
Healthy Volunteers HVTN 302: HIV Vaccine Trial for Healthy, HIV Negative Adults, Ages 18-55
COVID-19 (Coronavirus) C4671026 - Pfizer Pediatric Paxlovid Study